Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Wednesday 04 April, 2012

Summit Corporation PLC

Summit Corporation PLC : Directorate change - A...

Summit Corporation PLC : Directorate change - Appointment of Glyn Edwards as CEO

Summit Corporation plc
('Summit' or 'the Company')


Oxford, UK, 4 April 2012, Summit (AIM: SUMM), a UK drug discovery company, today announces that Mr Glyn Edwards has been appointed as the Company's new Chief Executive Officer.  Glyn will take up the position with immediate effect and will also join the Company's Board of Directors.  Dr Barry Price will reassume the position of Non-Executive Chairman of Summit.

Glyn Edwards has a wealth of expertise garnered from a thirty-year career in the life sciences industry, during which time he has held a number of senior executive and business development roles.  Glyn has a proven commercial track record of successfully partnering drug programmes with major pharmaceutical companies having completed a number of multi-million dollar headline licensing deals.  

Barry Price, PhD, Chairman of Summit commented: "The Board is delighted to appoint Glyn Edwards as Summit's new Chief Executive Officer because of his substantial experience of the life sciences industry and proven commercial track record.  The Company is entering a pivotal stage in its development as key drug programmes approach important milestones, and the Board is confident that under Glyn's leadership, Summit will generate value growth for our shareholders."


Glyn Edwards, Chief Executive Officer of Summit added:"I am pleased to be joining Summit at what I believe is an exciting stage in its development.  The Company has a number of promising drug programmes and an innovative technology platform, and I look forward to working with the team to uncover the potential of these assets."


Glyn Edwards holds 400,000 shares (0.21%) of the current issued share capital in the Company.  No further disclosures are required under Rule 17 and Schedule 2(g) of the AIM Rules.  Glyn is currently a Director of Oxford Cancer Biomarkers Limited and the National Cancer Research Institute. Glyn is the interim Chief Executive Officer of the UK trade body, the BioIndustry Association ('BIA') and he will be stepping down from this role shortly.  

- END -

For more information, please contact:

Barry Price, PhD,
Glyn Edwards
Richard Pye, PhD
Tel: +44 (0)1235 443 939
Singer Capital Markets
(Nominated Adviser and Joint broker)
Shaun Dobson / Claes Spång

Tel: +44 (0)203 205 7500
Hybridan LLP
(Joint broker)
Claire Louise Noyce / Deepak Reddy

Tel: +44 (0)207 947 4350
Peckwater PR
(Financial public relations)
Tarquin Edwards

Tel: +44 (0)7879 458 364

Notes to Editors

About Glyn Edwards
Glyn Edwards is currently a Director of Oxford Cancer Biomarkers Limited and the National Cancer Research Institute and the interim Chief Executive Officer of the BioIndustry Association ('BIA'), a role from which he will step down from shortly.  He was previously Chief Executive Officer of Antisoma from 1998-2011 and prior to this he worked in a variety of business development roles in the biotech and healthcare industries.  Glyn was also a member of the BIA Board and a director of Elara Associates Limited, a small consultancy business.  Mr Edwards has a BSc in Biochemistry from Bristol University and an MSc in Economics from the London Business School.  Glyn was made a Member of the British Empire as recognition for his services to the biotechnology industry.

About Summit
Summit is an Oxford, UK based drug discovery Company with an innovative Seglin(TM) technology platform for the discovery of new medicines and a portfolio of drug programme assets.  Summit's programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.  Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.  Further information is available at

Forward Looking Statements
This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Summit Corporation PLC via Thomson Reuters ONE